Abstract
Background As economic burden makes it increasingly difficult for countries to continue imposing control measures, it is vital for countries to make predictions using time series forecasting before making decisions on lifting the restrictions.
Aim Since apparent differences were noted in the disease transmission between the two South East Asian countries of India and Thailand, the study aims to draw comparative account of the progression of COVID 19 in near future between these two countries.
Methods The study used data of COVID 19 confirmed cases in India and Thailand from WHO COVID 19 situation reports during the time period between 25th March, 2020 and 14th May, 2020. After determination of stationarity in the data and differencing, observation of autocorrelation function (ACF) and partial autocorrelation function (PACF), Auto Regressive Integrated Moving Average (ARIMA) (2,2,1) model was used to forecast the COVID 19 confirmed cases in both these countries for two weeks (i.e. 28th May, 2020). IBM SPSS version 20.0 software was used for data analysis.
Results The study demonstrated a possible increasing trend in number of COVID 19 cases in India in the coming two weeks with an estimated point forecast of 1,28,772 (95% CI 115023–142520) by 28th May, 2020. A stationary phase was forecasted for Thailand with a difference of only 43 cases between 14th May (the last case of input data) and 28th May.
Conclusion The time series forecasting employed in the present study warrants thorough preparation on part of the Indian health care system and authorities and calls for caution with regard to decisions made on lifting the control measures. The difference in the time series forecasting between these two South East Asian countries also highlights the need for strengthening of public health systems.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors did not receive any funding
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data analyzed in this study is available.
